問卷

TPIDB > Search Result

Search Result

篩選

List

25Cases

2022-03-01 - 2024-10-29

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-11-01 - 2026-05-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-12-13 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-12-01 - 2025-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-04-01 - 2027-11-30

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-08-25 - 2025-12-19

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2025-07-31 - 2028-09-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2025-03-31 - 2028-06-30

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2022-10-01 - 2026-01-16

Phase III

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis
  • Condition/Disease

    Adult patients with candidemia and/or invasive candidiasis

  • Test Drug

    Fosmanogepix CANCIDAS Fosmanogepix Caspofungin Fluconazole

Participate Sites
2Sites

Recruiting2Sites

2020-06-01 - 2022-12-31

Phase I

A Phase I, Open-Label, Multi-Dose Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients
  • Condition/Disease

    Anti-infectives for systemic use

  • Test Drug

    UB-421 SC (dB4C7C22-6 mAb)

Participate Sites
3Sites

Recruiting3Sites

1 2 3